Guide to the Pharmacological Management of End of Life (Terminal) Symptoms in Residential Aged Care Residents: A Resource for General Practitioners

This document is licensed under a Creative Commons Attribution-NonCommercial-NonDerivs 3.0 Australia licence. To view a copy of this licence visit:

http://creativecommons.org/licenses/by-nc-nd/3.0/

© State of Queensland (Queensland Health) 2015

In essence you are free to copy, distribute and transmit the work in its current form for non-commercial purposes. You must attribute the work in the manner specified by the authors. You may not alter, transform or build upon this work.

Recommended Citation


Enquiries

All enquiries about this document should be directed to:

Brisbane South Palliative Care Collaborative (Queensland Health)
Email: bspcc@health.qld.gov.au

An electronic copy of this resource can be downloaded at: http://www.caresearch.com.au/PAToolkit

Acknowledgements

This resource was developed as part of the National Rollout of the Palliative Approach Toolkit for Residential Aged Care Facilities Project. The Project was funded by the Australian Government Department of Social Services under the Encouraging Better Practice in Aged Care (EBPAC) Initiative.

Brisbane South Palliative Care Collaborative would like to thank the following for assistance in developing this resource:

• The Australian and New Zealand Society of Palliative Medicine (ANZSPM)
• Steering Committee for the National Rollout of the Palliative Approach Toolkit for Residential Aged Care Facilities
• Clinical Education Reference Group for the National Rollout of the Palliative Approach Toolkit for Residential Aged Care Facilities
• Clinical staff from Metro South Palliative Care Service (Queensland Health)

Disclaimer

This document was produced by the Brisbane South Palliative Care Collaborative as an educational resource and is intended for use by health professionals working in Australian residential aged care. The resource has been prepared to provide information on the use of medications in contributing to optimal symptom management during the terminal phase of a resident’s life.

Brisbane South Palliative Care Collaborative has exercised due care in ensuring that information and materials in this resource are based on the available best practice literature or, in the absence of this literature, expert opinion. The information and materials in this resource do not constitute professional advice and should not be relied on as such.

It is beyond the scope of this resource to examine and cover in detail all elements of clinical practice that need to be addressed prior to prescribing medication to manage end of life (terminal) symptoms. Clinical information and materials in this resource do not replace clinical judgement. Individual clinicians and other health professionals remain responsible for:

• Comprehensive assessment of the resident and ensuring the appropriateness and suitability of a particular medication and dosage prior to prescribing or administering the medication.
• Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct.

Neither Brisbane South Palliative Care Collaborative nor any person associated with the preparation of this resource accepts liability for any injury, loss or damage incurred by use of or reliance upon the information and materials provided in this resource.
About this Guide

Context
Residents who are dying commonly experience distressing symptoms in the last days and hours of life. High quality end of life care requires ongoing assessment of the resident and timely use of pharmacological and non-pharmacological strategies to address emerging symptoms. Failure to do so can result in poor resident/family outcomes as well as poor health system outcomes if dying residents are inappropriately transferred to emergency departments/hospital wards.

General Practitioners (GPs) have a central role in leading and case managing the end of life care provided by multidisciplinary clinical teams in residential aged care settings. As such:
- GPs require high level and up-to-date knowledge about end of life symptom management and the appropriate and safe use of palliative care medications for residents.
- GPs should work proactively to ensure immediate access to these medications to relieve symptoms as they occur (e.g. by pre-emptively prescribing necessary medications for subsequent administration if symptoms occur).

Important
Whereas palliative care may be appropriate over a longer period (e.g. several months), end of life care focuses on the final days or week of life. This guide focuses on the pharmacological management of end of life symptoms commonly experienced by residential aged care residents in the last days or hours of life.

Focus
This guide has been developed as part of the Residential Aged Care Palliative Approach (PA) Toolkit (for further information visit www.caresearch.com.au/PAToolkit). The guide has been designed specifically:
- For use by GPs when leading and case managing the end of life care provided by multidisciplinary clinical teams in residential aged care settings. The pharmacological information set out in this guide is also relevant to the nurse practitioner scope of practice.
- To support GPs in their proactive clinical management of common end of life symptoms experienced by residential aged care residents.
- To facilitate the optimal care of residents who have entered the terminal phase of their lives. It is expected that these residents will have been commenced on an end of life care pathway and that their prognosis is limited to days.

Key Features
This guide includes:
- A consensus-based list of medications, endorsed by The Australian and New Zealand Society of Palliative Medicine (ANZSPM), suitable for use in residential aged care for the management of terminal symptoms.
- A table summarising the uses, doses and routes of administration of the medications endorsed by ANZSPM.
- Flowcharts summarising the pharmacological management of four end of life symptoms within a quality use of medicine framework as set out in the Australian National Medicines Policy and inclusive of local jurisdiction legislative considerations. The four symptoms are:
  - Nausea and vomiting
  - Pain
  - Respiratory distress
  - Restlessness and agitation

* These teams often include residential aged care facility staff (e.g. clinical manager, registered and enrolled nurses) as well as other health professionals employed external to the facility (e.g. local pharmacists, staff from specialist palliative care services).
Quality Pharmacological Management of End of Life (Terminal) Symptoms

Key Principles

Residents who are in the terminal (or dying) phase are clinically unstable – symptoms can emerge at any time which may require pharmacological intervention. To ensure a good death, residents require proactive pharmacological management.

Key principles underlying this pharmacological management include:

• Medications are prescribed, obtained, charted and administered according to the Australian National Medicines Policy and in accordance with regional jurisdictional requirements and local facility policies and procedures.1,7,8
• Knowledge by the resident, or their substitute decision maker if appropriate, that the dying process is occurring and that medication administration may improve the quality of death.9
• Consent given by the resident, or their substitute decision maker if appropriate, to receive medications for the treatment of terminal symptoms.9
• If a medication is considered necessary, the most appropriate medicine is chosen and used safely and effectively.9,10
• Medications are immediately available to ensure optimal symptom control.1,7,9
• Charted medication doses are based on frequent assessment of the resident and are appropriate to the severity of the symptom[s]. Persistent symptoms are treated with regular doses of medication while as needed doses of medication are charted to cover ‘break through’ symptoms. Medications are administered by the most reliable route.9,10
• Responses to administered medications are charted and adverse reactions noted and notified.9,10 The Therapeutic Goods Administration encourages reporting of all suspected adverse reactions to prescription, over-the-counter and complementary medicines. Information on how to lodge a report together with the ‘blue card’ adverse reaction reporting form are available online at http://www.tga.gov.au/reporting-medicine-and-vaccine-adverse-events
• Action is taken in the event of a medication error occurring - e.g. under- or over-dosing according to local policy and procedure documentation.

Consensus-Based List of End of Life (Terminal) Symptom Medications

Table 1 provides a consensus-based list of eight medications, endorsed by The Australian and New Zealand Society of Palliative Medicine (ANZSPM), suitable for use in residential aged care for the management of terminal symptoms. Information about the uses, doses and routes of administration of each of these medications is summarised in Table 2.
### Table 1: End of Life (Terminal) Symptom Management Medications for Residential Aged Care Facilities

A consensus-based list of medications, endorsed by The Australian and New Zealand Society of Palliative Medicine (ANZSPM), suitable for use in residential aged care for the management of terminal symptoms.

<table>
<thead>
<tr>
<th>MEDICATION</th>
<th>DOSE</th>
<th>STOCK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clonazepam drops*</td>
<td>2.5 mg/ml</td>
<td>1 bottle (10 mls)</td>
</tr>
<tr>
<td>Fentanyl Citrate injection**</td>
<td>100 mcg/2 ml</td>
<td>10 ampoules</td>
</tr>
<tr>
<td>Haloperidol injection</td>
<td>5 mg/ml</td>
<td>10 ampoules</td>
</tr>
<tr>
<td>Hydromorphone injection</td>
<td>2 mg/ml</td>
<td>5 ampoules</td>
</tr>
<tr>
<td>Hyoscine Butylbromide (Buscopan) injection***</td>
<td>20 mg/ml</td>
<td>5 ampoules</td>
</tr>
<tr>
<td>Metoclopramide injection</td>
<td>10 mg/2 ml</td>
<td>10 ampoules</td>
</tr>
<tr>
<td>Midazolam injection**</td>
<td>5 mg/ml</td>
<td>10 ampoules</td>
</tr>
<tr>
<td>Morphine Sulphate injection</td>
<td>10 mg/ml</td>
<td>5 ampoules</td>
</tr>
</tbody>
</table>

**Notes:**
- * Non-PBS unless for seizure control
- ** Not on the PBS
- *** Listed on PBS for palliative patients

© State of Queensland (Queensland Health) 2013. Developed by Brisbane South Palliative Care Collaborative (Queensland Health)

Endorsed by The Australian and New Zealand Society of Palliative Medicine Inc (ANZSPM), July 2013.
# Table 2: Palliative Care in Residential Aged Care Facilities: Medications Commonly Used to Manage Symptoms at End of Life

An educational resource summarising the uses, doses and routes of administration of the medications endorsed by ANZSPM

**IMPORTANT:** The information presented here is for educational benefit only. It is a general guide to appropriate practice and is subordinate to the clinical judgement of the treating clinician. Much of the content in the table below was obtained from: Palliative Care Expert Group. Therapeutic Guidelines: Palliative Care. Version 3. Melbourne: Therapeutic Guidelines Limited; 2010

© State of Queensland (Queensland Health) 2013. Developed by Brisbane South Palliative Care Collaborative (Queensland Health) Endorsed by The Australian and New Zealand Society of Palliative Medicine Inc (ANZSPM), July 2013.

### DRUG

<table>
<thead>
<tr>
<th>DRUG</th>
<th>USUAL DOSE AND FREQUENCY OF ADMINISTRATION RANGE</th>
<th>USUAL ROUTE OF ADMINISTRATION</th>
<th>REASONS FOR USE</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clonazepam</td>
<td>0.3 to 1 mg, 4 hourly PRN</td>
<td>Oral liquid formulation</td>
<td>Anxiety</td>
<td>• Recommendation: low initial dosing and frequent reassessment</td>
</tr>
<tr>
<td></td>
<td>0.25 to 1 mg, 4 hourly PRN</td>
<td>Subcutaneous bolus</td>
<td>Prevention / treatment of seizures</td>
<td>• Oral administration: count oral drops onto a spoon prior to putting into mouth. Three drops = 0.3 mg</td>
</tr>
<tr>
<td></td>
<td>1 to 4 mg by CSCI over 24 hours</td>
<td>CSCI</td>
<td>Terminal agitation / restlessness</td>
<td>• Oral clonazepam is well absorbed by buccal mucosa</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sedation</td>
<td>• Subcutaneous administration: clonazepam absorbs to PVC so should preferably be given using PVC-free equipment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Subcutaneous bolus</td>
<td>Short acting (i.e. effective for 1 to 1.5 hours so may need to be given more frequently than other narcotics)</td>
<td>• Equianalgesic dose: 150 mcg fentanyl subcut = 10 mg morphine subcut</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CSCI</td>
<td>Delirium</td>
<td>• Recommendation: low initial dosing and frequent reassessment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Psychosis</td>
<td>• Antiemetic doses are lower than antipsychotic doses</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Terminal agitation / restlessness</td>
<td>• Consult specialist palliative care service for more detailed information regarding dosage</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nausea</td>
<td>• Observe for extrapyramidal side effects e.g. akathisia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Vomiting</td>
<td></td>
</tr>
<tr>
<td>Fentanyl</td>
<td>25 to 200 mcg, 2 hourly PRN</td>
<td>Subcutaneous bolus</td>
<td>Pain</td>
<td>• Equianalgesic dose: 150 mcg fentanyl subcut = 10 mg morphine subcut</td>
</tr>
<tr>
<td></td>
<td>100 to 800 mcg as CSCI over 24 hours</td>
<td>CSCI</td>
<td>SOB</td>
<td></td>
</tr>
<tr>
<td>Haloperidol</td>
<td>0.5 to 1.5 mg, 12 hourly PRN</td>
<td>Subcutaneous bolus</td>
<td>Delirium</td>
<td>• Recommendation: low initial dosing and frequent reassessment</td>
</tr>
<tr>
<td></td>
<td>1 to 5 mg by CSCI over 24 hours</td>
<td>CSCI</td>
<td>Psychosis</td>
<td>• Antiemetic doses are lower than antipsychotic doses</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Terminal agitation / restlessness</td>
<td>• Consult specialist palliative care service for more detailed information regarding dosage</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nausea</td>
<td>• Observe for extrapyramidal side effects e.g. akathisia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Vomiting</td>
<td>• Antiemetic doses are lower than antipsychotic doses</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>Hydromorphone is 5 times stronger than morphine; only to be used in consultation with specialist palliative care service</td>
<td>Subcutaneous bolus</td>
<td>Pain</td>
<td>• Synthetic form of morphine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CSCI</td>
<td>SOB</td>
<td>• Potential for medication errors due to confusion with morphine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Respiratory secretions at end of life</td>
<td>• Equianalgesic dose: 2 mg hydromorphone subcut = 10 mg morphine subcut</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Colic</td>
<td></td>
</tr>
<tr>
<td>Hyoscine Butylbromide</td>
<td>20 mg, 2 to 4 hourly PRN</td>
<td>Subcutaneous bolus</td>
<td>Respiratory secretions at end of life</td>
<td>Most frequently used to treat respiratory secretions. Most effective if given early [i.e. as soon as ‘noisy respirations’ begin]</td>
</tr>
<tr>
<td></td>
<td>20 to 60 mg by CSCI over 24 hours</td>
<td>CSCI</td>
<td>Colic</td>
<td></td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>10 to 20 mg, 6 hourly PRN</td>
<td>Subcutaneous bolus</td>
<td>Nausea</td>
<td>• Observe for extrapyramidal side effects e.g. akathisia</td>
</tr>
<tr>
<td></td>
<td>10 to 80 mg by CSCI over 24 hours</td>
<td>CSCI</td>
<td>Vomiting</td>
<td></td>
</tr>
<tr>
<td>Midazolam</td>
<td>2.5 to 10 mg, 2 to 4 hourly PRN</td>
<td>Subcutaneous or sublingual bolus</td>
<td>Anxiety</td>
<td>• Rapid onset, short acting benzodiazepine</td>
</tr>
<tr>
<td></td>
<td>5 to 30 mgs by CSCI over 24 hours</td>
<td>CSCI</td>
<td>Seizures</td>
<td>• Rapid onset, short acting benzodiazepine</td>
</tr>
<tr>
<td></td>
<td>[occasionally higher doses used]</td>
<td></td>
<td>Terminal agitation / restlessness</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sedation</td>
<td></td>
</tr>
<tr>
<td>Morphine Sulphate</td>
<td>2.5 to 20 mg, 2 to 4 hourly PRN</td>
<td>Subcutaneous bolus</td>
<td>Pain</td>
<td>Not tolerated in residents with poor renal function as can cause confusion, myoclonus and other effects of narcotic toxicity</td>
</tr>
<tr>
<td></td>
<td>5 to 200 mg by CSCI over 24 hours</td>
<td>CSCI</td>
<td>SOB</td>
<td>• Equianalgesic dose: 5 mg morphine subcut = 15 mg oral morphine</td>
</tr>
<tr>
<td></td>
<td>[theoretically no ceiling dose]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Subcutaneous infusions are an effective way to give a combination of medications to people who cannot swallow, are nauseated and/or have complex symptoms.

**KEY:**
- CSCI: continuous subcutaneous infusion
- PRN: as needed by predetermined time
- Subcut: subcutaneous
- SOB: shortness of breath
- PVC: polyvinyl chloride (plastic)

© State of Queensland (Queensland Health) 2013. Developed by Brisbane South Palliative Care Collaborative (Queensland Health) Endorsed by The Australian and New Zealand Society of Palliative Medicine Inc (ANZSPM), July 2013.
Symptom Management Flowcharts

Using the Flowcharts

The following flowcharts present a stepwise approach to the use of medications in managing distressing symptoms that are commonly experienced by dying residents in the terminal phase:

- Flowchart 1: Nausea and Vomiting
- Flowchart 2: Pain
- Flowchart 3: Respiratory Distress
- Flowchart 4: Restlessness and Agitation

The flowcharts are intended to assist clinical staff in making best practice and, where possible, evidence-based decisions about the care of residents who are dying and who have been commenced on the Residential Aged Care End of Life Care Pathway (RAC EoLCP).

What is the Residential Aged Care End of Life Care Pathway (RAC EoLCP)?

The RAC EoLCP is a clinical tool developed by the Brisbane South Palliative Care Collaborative (BSPCC) for use by Australian RACFs in documenting and delivering resident-centred end of life (terminal) care.

The RAC EoLCP form:

- Is a consensus-based, best practice guide for providing care during the last days of a resident’s life.
- Is made up of five sections which facilitate the comprehensive documentation and delivery of end of life (terminal) care by RACFs.

When implemented in conjunction with a palliative approach framework, the RAC EoLCP has been shown to improve outcomes for dying residents and enhance the quality of end of life (terminal) care provided by RACFs.6 Detailed information about the RAC EoLCP is provided in the following PA Toolkit resources:

- Module 2: Key Processes
- Educational DVD: How to Use the Residential Aged Care End of Life Care Pathway [RAC EoLCP]

The flowcharts are a guide only and do not replace good clinical decision-making based on a detailed knowledge of the resident’s health history and a comprehensive assessment of the resident’s current condition and symptoms. Choice of medication[s] and specific dose[s] remain the responsibility of the prescribing medical officer or nurse practitioner. Registered and enrolled nurses are responsible for:

(a) regularly assessing symptoms;
(b) administering PRN medications when required;
(c) regularly monitoring and documenting the effectiveness of prescribed medication[s]; and
(d) identifying and reporting side effects/adverse reactions caused by prescribed medication.

The flowcharts are a guide only and do not replace good clinical decision-making.
Careful monitoring, titration and frequent assessment of medication effectiveness, side effects and adverse reactions are essential.
Each flowchart is accompanied by a brief summary of the current evidence used to inform the recommendations made about the pharmacological management of each symptom. The level of evidence currently available is identified in each summary. High level scientific evidence supporting the pharmacological management of end of life (terminal) symptoms in older people remains limited and, as a result, consensus-based expert opinion about best practice is often relied upon to guide clinical decision-making.

**Key points to consider in the pharmacological management of end of life (terminal) symptoms experienced by residents in RACFs** include:

- The resident and/or their substitute decision maker should be aware that the resident is dying and support the use of medications to manage end of life (terminal) symptoms.
- Medications and doses prescribed should be based on careful assessment of the dying resident's condition and symptoms.
- Doses should be proportionate to the severity of symptoms and response to treatment should be regularly reassessed.
- Medications that have minimal therapeutic benefit in the terminal phase of life should be ceased.
- The burden of how medications are given and of potential side effects should be minimised. Palliative care medications at the end of life are usually given via the subcutaneous route, which is generally the least invasive and most reliable route in the dying resident.
- Persistent symptoms require regular rather than PRN (as needed) orders.
- Use of regular medications to manage symptoms does not preclude the need for appropriate breakthrough dose orders.
  
  PRN orders should be written for intermittent symptoms and to cover possible breakthrough events for persistent symptoms.
- Anticipatory PRN prescribing for problems which may occur during the dying process is important for good end of life (terminal) care as it will ensure that medications are easily accessible when required.

[*Adapted from CareSearch: Symptom Management at the End of Life*]

These points have been used to inform recommendations made in the following set of four flowcharts.
Flowchart 1: Pharmacological Management of Nausea and Vomiting for Residents on the Residential Aged Care End of Life Care Pathway (RAC EoLCP)

**SYMPTOMS PRESENT**

Administer appropriate medication as currently charted for nausea and vomiting. Request MO/NP to immediately review current drugs, both regular and PRN orders.

**SYMPTOMS ABSENT**

Pre-emptively organise medications to manage nausea and vomiting. Request MO/NP to review current drugs, both regular and PRN orders.

---

**YES**

Is an antiemetic prescribed?

**NO**

1. Review current antiemetic and dose:
   - If nausea and vomiting persist, or if resident using regular oral antiemetic and unable to swallow, consider converting to metoclopramide 20 to 30 mg administered by CSCI using a syringe driver over 24 hours.
   - Ensure order written for metoclopramide 10 mg subcut PRN q tds.

2. If nausea and vomiting persist consider trial of haloperidol 0.5 to 1.5 mg subcut PRN q bd.

3. If haloperidol appears to be more effective than metoclopramide in managing nausea and vomiting consider changing to CSCI of haloperidol using a syringe driver over 24 hours.

4. Regularly reassess symptom management and continue to administer PRN metoclopramide or PRN haloperidol for breakthrough nausea and vomiting.

5. Observe closely for extrapyramidal side effects of metoclopramide/haloperidol e.g. akathisia.

---

Even if symptoms absent, continue to review regularly for nausea and vomiting. If resident experiencing nausea and vomiting refer to the ‘Symptoms present’ column.

---

If greater than 3 doses of PRN metoclopramide 10 mg subcut required over 24 hour period, or if prescribed haloperidol dose ineffective over 24 hour period, request MO/NP review to consider changes in medication and syringe driver orders.

---

If symptom management remains inadequate despite above interventions contact MO/NP or palliative care service for further advice.

**KEY:**
- **bd** twice daily
- **B/T** breakthrough
- **CSCI** continuous subcutaneous infusion
- **MO** Medical Officer
- **NP** Nurse Practitioner
- **PRN** as needed by predetermined time
- **q** every
- **Subcut** subcutaneous
- **tds** three times per day

© State of Queensland (Queensland Health) 2013. Developed by Brisbane South Palliative Care Collaborative (Queensland Health)
**Key messages**

- The RAC EoLCP is a consensus-based best practice guide to providing care for residents in the last days of life.
- Pre-emptive prescribing will ensure that in the last days and hours of a resident’s life there is no delay in responding to a symptom if it occurs.
- Residents on the RAC EoLCP require 2 hourly symptom assessment. This allows for emergent symptoms to be detected quickly and treated pharmacologically if required. Efficacy of administered medications should be evaluated and documented.
- Always consider non-pharmacological interventions in addition to the pharmacological management of end of life (terminal) symptoms.

**Summary of clinical evidence**

- Factors contributing to nausea and vomiting in a resident with a life-limiting illness may include but are not limited to: drug toxicity, urinary tract infection, constipation, diseases of the gastrointestinal tract, metabolic and biochemical disturbance and organ failure. Cause(s) of nausea and vomiting in the last days of life may be unidentifiable and multi-factorial. (Level V)
- Nausea is often under recognised and under treated. (Level I)
- There is limited evidence to guide the use of antiemetic therapy in the elderly. (Level V)
- Opioids commonly cause nausea and vomiting. Metoclopramide has been shown to be effective in the management of nausea and vomiting in patients with cancer who are on opioid therapy. (Level V), (Level I), (Level V)
- Haloperidol can be trialled to manage nausea and vomiting if metoclopramide is ineffective. (Level V), (Level I)
- Metoclopramide or haloperidol can cause extrapyramidal side effects. These medications need to be avoided or used with caution in residents with neurodegenerative disorders such as Parkinson's disease. (Level V), (Level V)
- Subcutaneous infusion of antiemetics delivered via a syringe driver has been shown to be effective in managing persistent symptoms of nausea and vomiting. (Level V)

**For further information**

CareSearch: RAC Hub

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180521/


Flowchart 2: Pharmacological Management of Pain for Residents on the Residential Aged Care End of Life Care Pathway (RAC EoLCP)

### SYMPTOMS PRESENT

**Review regularly for symptoms of pain** (see RAC EoLCP, Comfort Care Chart, page 5)

Administer appropriate medication as currently charted for pain. Request MO/NP to review immediately current drugs, both regular and PRN orders.

**Are regular or PRN opioids prescribed for pain?**

**NO**

1. **Review current opioid dose:**
   - If resident using regular opioids and unable to swallow consider:
     - converting regular oral opioids to appropriate subcut dose administered by CSCI using a syringe driver over 24 hours (see Opioid Conversion Chart)
   - If pain causing distress and/or if multiple PRN opioids administered in previous 24 hours to manage pain, calculate the total dose of B/T opioids over previous 24 hours and add to syringe driver opioid dose or titrate up the opioid dose administered by syringe driver in previous 24 hours by 30%
   - If opioid patch in situ consider:
     - continuing patch at same dose and giving opioid PRN subcut dose for B/T pain (may require advice from specialist palliative care team to calculate appropriate PRN dose)
     OR
     - converting patch to appropriate subcut opioid dose administered by CSCI using a syringe driver over 24 hours (see Opioid Conversion Chart)
     - Ensure order written for PRN dose. PRN order = 1/12 q 2hrly of total daily subcut dose
2. If pain persists, administer PRN opioid dose
3. Assess effectiveness of administered medication and continue administering opioids as required

If greater than 3 doses of PRN opioids required for B/T pain over 24 hour period, request MO/NP review to consider changes to medication and syringe driver orders

**YES**

1. **Write/request opioid order for pain management. Consider:**
   - Morphine 2.5 to 5 mg subcut PRN q 2hrly
     OR
     - Fentanyl 25 to 50 mcg subcut PRN q 2hrly
     OR
     - Hydromorphone 0.5 to 1 mg subcut PRN q 2hrly
2. If pain present, administer PRN opioid dose
3. Assess effectiveness of administered medication and continue administering opioids as required

### SYMPTOMS ABSENT

Pre-emptively organise medications to manage pain. Request MO/NP to review current drugs, both regular and PRN orders.

**Are regular or PRN opioids prescribed for pain?**

**NO**

1. **Write/request opioid order for pain management. Consider:**
   - Morphine 2.5 to 5 mg subcut PRN q 2hrly
     OR
     - Fentanyl 25 to 50 mcg subcut PRN q 2hrly
     OR
     - Hydromorphone 0.5 to 1 mg subcut PRN q 2hrly

**YES**

1. **Review current opioid dose:**
   - If resident using regular oral opioids and unable to swallow consider:
     - converting regular oral opioids to appropriate subcut dose administered by CSCI using a syringe driver over 24 hours (see Opioid Conversion Chart)
   - If opioid patch in situ consider:
     - continuing patch at same dose
     OR
     - converting patch to appropriate subcut opioid dose administered by CSCI using a syringe driver over 24 hours (see Opioid Conversion Chart)
   - Ensure order written for opioid subcut PRN dose. PRN order = 1/12 q 2hrly of total daily subcut dose
   - If resident only has oral PRN opioid dose change to equivalent dose subcut PRN

Even if symptoms absent, continue to review regularly for pain. If resident experiencing pain refer to the ‘Symptoms present’ column

**If symptom management remains inadequate despite above interventions contact MO/NP or palliative care service for further advice**

**KEY:**
- **bd** twice daily
- **B/T** breakthrough
- **CSCI** continuous subcutaneous infusion
- **MO** Medical Officer
- **NP** Nurse Practitioner
- **PRN** as needed by predetermined time
- **q** every
- **Subcut** subcutaneous
- **tds** three times per day

© State of Queensland (Queensland Health) 2013. Developed by Brisbane South Palliative Care Collaborative (Queensland Health)
**Key messages**

- The RAC EoLCP is a consensus-based best practice guide to providing care for residents in the last days of life.
- Pre-emptive prescribing will ensure that in the last days and hours of a resident’s life there is no delay in responding to a symptom if it occurs.
- Residents on the RAC EoLCP require 2 hourly symptom assessment. This allows for emergent symptoms to be detected quickly and treated pharmacologically if required. Efficacy of administered medications should be evaluated and documented.
- Always consider non-pharmacological interventions in addition to the pharmacological management of end of life (terminal) symptoms.

**Summary of clinical evidence**

- Studies indicate that pain is a common problem experienced by elderly people living in RACFs. The prevalence of persistent pain in this population is estimated to be between 49% and 80%.  
  \[\text{Level III-2}, 17 \text{ Level V}\]
- Opioids are effective and generally well tolerated in the elderly.  
  \[\text{Level V}\]
- Opioid naïve residents requiring opioids to manage pain should be commenced on the lowest opioid dose possible. Careful upward titration minimises the risk of toxicity.  
  \[\text{Level I}, 19 \text{ Level V}\]
- Common side effects of opioid administration include constipation, nausea and vomiting, dizziness and sedation. Most side effects diminish with continued use except for constipation which will persist. A laxative order should be in place to minimise this problem.  
  \[\text{Level V}\]
- Morphine should be avoided in residents with severe renal failure (eGFR<30) due to the build up of toxic metabolites. Fentanyl has no active metabolites of relevance and has been identified as the opioid that is least likely to cause harm in residents with severe renal impairment when used appropriately.  
  \[\text{Level I}\]
- To optimise relief of persistent pain, opioids should be administered on an ‘around-the-clock’ basis according to the duration of action of the prescribed opioid.  
  \[\text{Level V}\]
- Breakthrough pain occurs commonly in people who are receiving opioids for persistent pain. In addition to the regular opioid dose, a PRN breakthrough opioid dose should be prescribed at 1/12th to 1/6th of the 24 hour dose.  
  \[\text{Level V}\]
- Transdermal opioid patches (buprenorphine and fentanyl) are not suitable to commence in the last days of life. Transdermal opioid patches have a prolonged onset time and therefore rapid, safe dose titration to manage escalating symptoms is not possible.  
  \[\text{Level I}\]
- When initiating opioids in the last days of life or when oral route is no longer viable, a continuous subcutaneous infusion using a syringe driver is the preferred route of administration.  
  \[\text{Level V}, 24 \text{ Level V}\]

**For further information**

- CareSearch: RAC Hub
- Guidelines for LCP Drug Prescribing in Advanced Chronic Kidney Disease
- Pain in Residential Aged Care Facilities: Management Strategies
- Residential Aged Care Palliative Approach Toolkit: Module 3 – Clinical Care
- National Collaborative Guidelines for Cancer: Opioids in Palliative Care - Safe and Effective Prescribing of Strong Opioids for Pain in Palliative Care of Adults
Flowchart 3: Pharmacological Management of Respiratory Distress for Residents on the Residential Aged Care End of Life Care Pathway (RAC EoLCP)

Respiratory distress includes the symptoms of A. shortness of breath (observed or reported), B. associated anxiety and/or C. excessive secretions.

SYMPTOMS PRESENT

Review regularly for symptoms of respiratory distress (see RAC EoLCP, Comfort Care Chart, page 5)

YES

Administer appropriate medication[s] as currently charted for respiratory distress. Request MO/NP to review immediately current drugs, both regular and PRN orders

1. Review current opioid dose:
   - If resident using regular opioids and unable to swallow consider converting regular oral opioids to appropriate subcut dose administered by CSCI using syringe driver over 24 hours
   - If resident very distressed and/or requiring multiple PRN opioids to manage breathlessness, may need higher dose in syringe driver but generally advised not to titrate above 30% of previous daily requirements
   - If opioid patch in situ continue at same dose and administer PRN medication for B/T symptoms
   OR
   - Convert patch to appropriate subcut opioid dose administered by CSCI using a syringe driver (see Opioid Conversion Chart)
   - Ensure order written for PRN dose. PRN order = 1/12 q 2hrly of total daily subcut dose
2. If shortness of breath present administer opioid PRN dose
3. Assess effectiveness of administered medication and continue administering opioids as required

YES

A. Shortness of breath: Are opioids prescribed for any reason?

1. Write/request opioid order for shortness of breath. Consider:
   - Morphine 1.5 to 2.5 mg subcut PRN q 2hrly
   OR
   - Fentanyl 25 to 50 mcg subcut PRN q 2hrly
   OR
   - Hydromorphone 0.25 to 0.5 mg subcut PRN q 2hrly
2. If shortness of breath present administer opioid PRN dose
3. Assess effectiveness of administered medication and continue administering opioids as required

NO

YES

B. Associated anxiety: Are benzodiazepines already prescribed to manage anxiety?

1. Review current benzodiazepine dose:
   - If resident using regular benzodiazepine tablets and unable to swallow, consider converting to subcut route via CSCI using syringe driver over 24 hours
   - Ensure order for PRN dose for anxiety
   - If resident only has PRN oral benzodiazepine tablet change to midazolam subcut or clonazepam subcut/oral drops
2. If anxiety present administer PRN dose of benzodiazepine
3. Assess effectiveness of administered medication and continue administering benzodiazepines as required

NO

YES

C. Excessive secretions: Write/request order for hyoscine butylbromide (Buscopan) 20 mg subcut PRN q 2 to 4hrly and administer if excessive respiratory secretions present

NO

If greater than 3 doses of any PRN medication required over 24 hour period, request MO/NP review to consider changes to medications and syringe driver orders

SYMPTOMS ABSENT

Pre-emptively organise medications to manage respiratory distress. Request MO/NP to review current drugs, both regular and PRN orders

YES

A. Shortness of breath: Are opioids prescribed for any reason?

1. Review current opioid dose:
   - If resident using regular opioids and unable to swallow consider converting regular oral opioids to appropriate subcut dose administered by CSCI using syringe driver over 24 hours
   - If resident very distressed and/or requiring multiple PRN opioids to manage breathlessness, may need higher dose in syringe driver but generally advised not to titrate above 30% of previous daily requirements
   - If opioid patch in situ continue at same dose and administer PRN medication for B/T symptoms
   OR
   - Convert patch to appropriate subcut opioid dose administered by CSCI using a syringe driver (see Opioid Conversion Chart)
   - Ensure order written for PRN dose. PRN order = 1/12 q 2hrly of total daily subcut dose
2. If shortness of breath present administer opioid PRN dose
3. Assess effectiveness of administered medication and continue administering opioids as required

NO

YES

B. Associated anxiety: Are benzodiazepines already prescribed to manage anxiety?

1. Review current benzodiazepine dose:
   - If resident using regular benzodiazepine tablets and unable to swallow, consider converting to subcut route via CSCI using syringe driver over 24 hours
   - Ensure order for PRN dose for anxiety
   - If resident only has PRN oral benzodiazepine tablet change to midazolam subcut or clonazepam subcut/oral drops
2. If anxiety present administer PRN dose of benzodiazepine
3. Assess effectiveness of administered medication and continue administering benzodiazepines as required

NO

YES

C. Excessive secretions: Pre-emptively write/request order for hyoscine butylbromide (Buscopan) 20 mg subcut PRN q 2 to 4hrly to manage excessive respiratory secretions

NO

Even if symptoms absent, continue to review regularly for any emerging symptoms of respiratory distress. If symptoms appear refer to the ‘Symptoms present’ column

If symptom management remains inadequate despite above interventions contact MO/NP or palliative care service for further advice

KEY:
- bd twice daily
- B/T breakthrough
- CSCI continuous subcutaneous infusion
- MO Medical Officer
- NP Nurse Practitioner
- PRN as needed by predetermined time
- q every
- Subcut subcutaneous
- tds three times per day

© State of Queensland (Queensland Health) 2013. Developed by Brisbane South Palliative Care Collaborative (Queensland Health)
Key messages

• The RAC EoLCP is a consensus-based best practice guide to providing care for residents in the last days of life.

• Pre-emptive prescribing will ensure that in the last days and hours of life there is no delay in responding to a symptom when it occurs.

• Oral and subcutaneous opioids administered in appropriate doses are safe and effective in managing shortness of breath.

• Residents on the RAC EoLCP require 2 hourly symptom assessment. This allows for emergent symptoms to be detected quickly and treated pharmacologically if required. Efficacy of medication administered should be evaluated and documented.

• Always consider non-pharmacological interventions in addition to the pharmacological management of end of life (terminal) symptoms.

Summary of clinical evidence

• Dyspnoea is a common symptom experienced in advanced disease irrespective of diagnosis. The prevalence and severity can increase over time particularly in the last days of life.  
  
  • Initiate simple measures to reduce dyspnoea such as repositioning the resident, tepid sponge if febrile and air flow across the face using rotating fan or open window.  
  
  • There is limited evidence to support the use of oxygen to manage dyspnoea at end of life. Oxygen has not been shown to relieve dyspnoea in non-hypoxic patients. If a resident is hypoxic, oxygen is recommended for provision of short term relief. Oxygen should be continued for residents who have required long term use for the management of breathlessness in chronic respiratory illnesses.  
  
  • Systemic opioids administered in appropriate doses are safe and effective in managing dyspnoea.  
  
  • Opioid naive residents requiring opioids to manage symptoms should be commenced on the lowest opioid dose possible. Careful upward titration minimises the risk of toxicity.  
  
  • Morphine should be avoided in residents with severe renal failure (eGFR<30) due to the build up of toxic metabolites. Fentanyl has no active metabolites of relevance and has been identified as an opioid that is least likely to cause harm in residents with severe renal impairment when used appropriately.  
  
  • Anxiety is often associated with shortness of breath and benzodiazepines are effective in managing this symptom.  
  
  • Excessive respiratory secretions can be very distressing for the resident and their family. Hyoscine butylbromide (Buscopan) reduces respiratory secretions. It does not cross the blood-brain barrier and therefore does not contribute to drowsiness or delirium.  

For further information

CareSearch: RAC Hub


Residential Aged Care Palliative Approach Toolkit: Module 3 – Clinical Care

Guide to the Pharmacological Management of End of Life (Terminal) Symptoms in Residential Aged Care Residents: A Resource for General Practitioners
**Flowchart 4: Pharmacological Management of Restlessness and Agitation for Residents on the Residential Aged Care End of Life Care Pathway (RAC EoLCP)**

**SYMPTOMS PRESENT**

**Review regularly for symptoms of restlessness and agitation (see RAC EoLCP, Comfort Care Chart, page 5)**

**YES**

A. Anxiety/emotional distress. Is a regular or PRN benzodiazepine prescribed for any reason?

1. Review current benzodiazepine dose:
   - If resident on long term regular benzodiazepine and unable to swallow, requires conversion to CSCI using syringe driver over 24 hours. Consider:
     - Midazolam - usual commencement dose 5 to 10 mg over 24 hours but may need higher dose depending on previous 24 hour dose
   - Clonazepam – usual commencement dose 1 to 2 mg over 24 hours but may need higher dose depending on previous 24 hour dose
   - Ensure written order for benzodiazepine dose PRN. Consider subcut midazolam or oral or subcut clonazepam
2. Administer PRN benzodiazepine dose
3. Assess effectiveness of administered medication and continue administering benzodiazepines as required
4. If symptoms persist consider use of antipsychotic medication

**NO**

1. Write/request order for benzodiazepine to manage restlessness and agitation. Consider:
   - Midazolam 2.5 to 5 mg subcut PRN q 4hrly
   - Clonazepam 0.25 to 0.5 mg oral drops or subcut PRN q 4hrly
2. Administer PRN benzodiazepine dose
3. Assess effectiveness of administered medication and continue administering benzodiazepines as required
4. If symptoms persist consider use of antipsychotic medication

**SYMPTOMS ABSENT**

**Pre-emptively organise medications to manage restlessness and agitation. Request MD/NP to review current drugs, both regular and PRN orders**

**YES**

A. Anxiety/emotional distress. Is a regular or PRN benzodiazepine prescribed for any reason?

1. Review current benzodiazepine dose:
   - If resident on long term regular benzodiazepine and unable to swallow, may need higher dose depending on previous 24 hour dose
   - Midazolam - usual commencement dose 5 to 10 mg over 24 hours but may need higher dose depending on previous 24 hour dose
   - Clonazepam – usual commencement dose 1 to 2 mg over 24 hours but may need higher dose depending on previous 24 hour dose
   - Ensure written order for benzodiazepine dose PRN. Consider subcut midazolam or oral or subcut clonazepam
2. Administer PRN benzodiazepine dose
3. Assess effectiveness of administered medication and continue administering benzodiazepines as required
4. If symptoms persist consider use of antipsychotic medication

**NO**

1. Write/request order for benzodiazepine to manage restlessness and agitation. Consider:
   - Midazolam 2.5 to 5 mg subcut PRN q 2hrly
   - Clonazepam 0.25 to 0.5 mg oral drops or subcut PRN q 2hrly
2. Administer PRN benzodiazepine dose
3. Assess effectiveness of administered medication and continue administering benzodiazepines as required
4. If symptoms persist consider use of antipsychotic medication

**B. Delirium. Is an antipsychotic [e.g. risperidone] prescribed for any reason?**

**YES**

1. Review current antipsychotic dose:
   - If resident on long term antipsychotic and unable to swallow, requires conversion to CSCI using syringe driver over 24 hours. Consider:
     - Haloperidol – commencement dose depends upon previous dose and severity of symptoms
   - If resident only has a PRN oral or wafer antipsychotic convert to subcut dose
2. Administer PRN antipsychotic dose
3. Assess effectiveness of administered medication and continue administering as required
4. Observe for extrapyramidal side effects

**NO**

1. Write/request antipsychotic order for persistent restlessness and agitation. Consider:
   - Haloperidol 0.5 to 1 mg subcut PRN q bd
2. Assess effectiveness of medication and continue administering antipsychotic as required
3. Observe for extrapyramidal side effects
4. If greater than 3 doses of any PRN medication required for B/T restlessness/agitation over 24 hour period, request MD/NP review to consider changes to medication and syringe driver orders

**Even if symptoms absent, continue to review regularly for restlessness and agitation. If resident experiencing restlessness and agitation refer to the “Symptoms present” column**

**KEY:**
- bd twice daily
- B/T breakthrough
- CSCI continuous subcutaneous infusion
- MD Medical Officer
- NP Nurse Practitioner
- PRN as needed by predetermined time
- q every
- Subcut subcutaneous
- tds three times per day

© State of Queensland (Queensland Health) 2013. Developed by Brisbane South Palliative Care Collaborative (Queensland Health)
Key messages

• The RAC EoLCP is a consensus-based best practice guide to providing care for residents in the last days of life.

• Pre-emptive prescribing will ensure that in the last days and hours of life there is no delay in responding to a symptom when it occurs.

• Restlessness and agitation at end of life is distressing not only for the resident but also for the family and care staff. If the condition is not well managed there is the potential for families/staff to retain distressing memories of the last days of a resident’s life.

• Residents on the RAC EoLCP require 2 hourly symptom assessment. This allows for emergent symptoms to be detected quickly and treated pharmacologically if required. Efficacy of medication administered should be evaluated and documented.

• Always consider non-pharmacological interventions in addition to the pharmacological management of end of life [terminal] symptoms.

Summary of clinical evidence

• Restlessness and agitation occur commonly at end of life and can often be attributed to multiple causes. Investigating the underlying cause may not be appropriate in the last days of life.10 (Level V)

• It is important to assess and manage factors which contribute to restlessness and agitation such as pain, urinary retention, rectal impaction, hypoxia, environmental factors, psychological and spiritual distress.10 (Level V)

• Non-pharmacological interventions have been shown to be effective in the prevention and management of delirium. These include a peaceful, familiar environment, the presence of a familiar person(s), avoidance of the dark and of bright lights and re-orientation of the resident.7 [Level V], 31 [Level I]

• Restlessness and agitation at end of life can be caused by anxiety and distress. The addition of a low dose benzodiazepine can be effective in managing these symptoms.32 [Level I], 33 [Level V]

• Low dose haloperidol is effective in managing restlessness and agitation associated with delirium.34 [Level I]

• Extrapyramidal side effects [dystonia and akathisia] occur more commonly in doses of haloperidol above 4.5 mg per day.34 [Level I]

For further information

CareSearch. RAC Hub

Clinical Practice Guidelines for the Management of Delirium in Older People [2006]. Melbourne: Victorian Government Department of Human Services


Residential Aged Care Palliative Approach Toolkit: Module 3 – Clinical Care

References


Glossary

**Analgesic:** A drug that provides symptomatic relief of pain but does not affect the underlying cause(s). Examples of analgesics include opioids, paracetamol and non-steroidal anti-inflammatory medications.

**Antiemetic:** A drug used for preventing or alleviating nausea and vomiting.

**Blood-brain barrier:** A network of blood vessels with closely spaced cells that make it difficult for potentially toxic substances to penetrate the blood vessel walls and enter the brain.

**Breakthrough dose:** Administration of an additional dose of opioid medication in response to pain that occurs between regular doses of an analgesic. This may be due to an increase in pain beyond the control of the baseline analgesia or it may reflect an occasional natural fluctuation in pain.

**Consensus-based:** An opinion or position reached by a group as a whole.

**Delirium:** A fluctuating state of confusion and rapid changes in brain function sometimes associated with hallucinations and restlessness. Symptoms may include inability to concentrate and disorganised thinking evidenced by rambling irrelevant and incoherent speech.

**Dyspnoea:** An awareness of uncomfortable breathing that can seriously affect quality of life.

**Evidence-based practice:** The integration of clinical expertise, patient values, and the best research evidence into the decision-making process for patient care.

**Extrapyramidal side effects:** Symptoms (including tremor, slurred speech, akathisia, dystonia, anxiety, distress, and paranoia) that are primarily associated with or are unusual reactions to neuroleptic (antipsychotic) medications.

**Hypoxia:** Inadequate oxygen supply to the cells and tissues of the body.

**Imprest drugs/emergency stock of medicines:** Restricted (Schedule 4) and controlled (Schedule 8) medications that are not supplied on prescription for a specific person but are instead obtained by an establishment (e.g. RACF) to be used as emergency stock.

**Levels of evidence:** A system to stratify evidence based on its quality.

**Non-pharmacological interventions:** Treatments that do not use medications to alleviate symptoms. Examples include massage, music therapy and aromatherapy.

**Opioid (or narcotic):** A group of substances that resemble morphine in their physiological and/or pharmacological effects (especially in their pain-relieving properties).

**Opioid naïve:** Refers to an individual who has either never had an opioid or who has not received repeated opioid dosing for a two to three week period.

**Opioid rotation:** Switching one opioid for another. This is required for patients with inadequate pain relief and/or intolerable opioid-related toxicities or adverse effects.

**Opioid titration:** Increasing or decreasing the dosage of an opioid. This requires regular assessment of the patient's pain and monitoring for possible side effects.

**Pharmacological interventions:** Treatments that involve the administration of medications to alleviate symptoms.

**Randomised control trial:** Trial conducted using participants selected in such a way as all known selective biasing factors have been eliminated. The trial involves the comparison of an experimental group with another group of participants, equal in all respects, who do not undergo the treatment being trialled.

**Substitute decision maker:** As people become less able to manage their affairs they may appoint a Power of Attorney or an Enduring Power of Attorney to assist them in future planning or decision-making.

**Terminal restlessness:** A common symptom appearing in the last hours to days of life. The person may show symptoms of being unable to relax, picking at clothing or sheets, confusion and agitation, and trying to climb out of bed.
Appendix A: Opioid Conversion Chart

- These conversions are a guide only. Residents in RACFs may vary in their response to different opioids.
- When rotating opioids for intolerable side effects, inadequate analgesia or to change the delivery route, it is advisable to reduce the dose by 25-50% due to incomplete cross-tolerance.
- Dose reduction is particularly important where pain escalation is not the reason for rotation to a different opioid.
- Following opioid rotation, close assessment of the resident is required to ensure the drug, the dose and the delivery method are tolerated and effective.
- Conversions involving methadone are complicated and prescribing should be restricted to medical specialists with experience in methadone prescribing.

Note: There is no validated opioid conversion tool and there can be significant variations across conversion charts.

**Oral Morphine to Other Oral Analgesics**

<table>
<thead>
<tr>
<th>Oral to Oral</th>
<th>Conversion ratio</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>morphine to codeine</td>
<td>1 : 8</td>
<td>oral morphine 7.5 mg ≈ codeine 60 mg</td>
</tr>
<tr>
<td>morphine to hydromorphone [Dilaudid IR &amp; Jurnista CR]</td>
<td>5 : 1</td>
<td>oral morphine 5 mg ≈ oral hydromorphone 1 mg</td>
</tr>
<tr>
<td>morphine to oxycodone [Endone IR/Oxynorm IR &amp; Oxycontin CR]</td>
<td>1.5 : 1</td>
<td>oral morphine 15 mg ≈ oral oxycodone 10 mg</td>
</tr>
<tr>
<td>morphine to oxycodone – naloxone (Targin CR)</td>
<td>1.5 : 1</td>
<td>oral morphine 15 mg ≈ oral oxycodone 10 mg + naloxone 5 mg</td>
</tr>
<tr>
<td>morphine to tramadol*</td>
<td>1 : 5</td>
<td>oral morphine 10 mg ≈ oral tramadol 50 mg</td>
</tr>
</tbody>
</table>

CR = Controlled Release IR = Immediate Release

**Oral Opioid to Parenteral Opioid (Subcut) – same drug to same drug**

<table>
<thead>
<tr>
<th>Oral to Oral</th>
<th>Parenteral</th>
<th>Conversion ratio</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>hydromorphone</td>
<td>hydromorphone</td>
<td>3 : 1</td>
<td>oral hydromorphone 60 mg ≈ subcutaneous hydromorphone 20 mg</td>
</tr>
<tr>
<td>morphine</td>
<td>morphine</td>
<td>3 : 1</td>
<td>oral morphine 30 mg ≈ subcutaneous morphine 10 mg</td>
</tr>
</tbody>
</table>

**Parenteral [Subcut] Morphine to Other Parenteral [Subcut] Opioid**

<table>
<thead>
<tr>
<th>From subcutaneous</th>
<th>To subcutaneous</th>
<th>Conversion ratio</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>morphine</td>
<td>fentanyl</td>
<td>100-150 : 1</td>
<td>morphine 10 mg ≈ fentanyl 150 mcg</td>
</tr>
<tr>
<td>morphine</td>
<td>hydromorphone</td>
<td>5 : 1</td>
<td>morphine 10 mg ≈ hydromorphone 2 mg</td>
</tr>
<tr>
<td>morphine</td>
<td>tramadol*</td>
<td>1 : 10</td>
<td>morphine 10 mg ≈ tramadol 100 mg</td>
</tr>
</tbody>
</table>

**Transdermal Buprenorphine to Oral Morphine**

<table>
<thead>
<tr>
<th>Buprenorphine patch strength</th>
<th>Daily oral morphine dose</th>
<th>Breakthrough oral morphine dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 micrograms per hour</td>
<td>12 mg daily</td>
<td>1 to 2 mg 2hrly PRN</td>
</tr>
<tr>
<td>10 micrograms per hour</td>
<td>24 mg daily</td>
<td>2 to 4 mg 2hrly PRN</td>
</tr>
</tbody>
</table>

**Transdermal Fentanyl to Oral Morphine**

<table>
<thead>
<tr>
<th>Fentanyl patch strength</th>
<th>Daily oral morphine dose</th>
<th>Breakthrough oral morphine dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 micrograms per hour</td>
<td>30 to 60 mg</td>
<td>2 to 4 mg 2hrly PRN</td>
</tr>
<tr>
<td>25 micrograms per hour</td>
<td>60 to 100 mg</td>
<td>5 to 10 mg 2hrly PRN</td>
</tr>
<tr>
<td>50 micrograms per hour</td>
<td>120 to 200 mg</td>
<td>10 to 20 mg 2hrly PRN</td>
</tr>
</tbody>
</table>

* Tramadol has a limited role in managing moderate to severe pain in palliative care.

**References:**

Appendix B: Additional Resources


Australian Medicines Handbook
https://shop.amh.net.au/products/books/2014

‘Blue card’ adverse reaction reporting form, Therapeutic Goods Administration

Decision Assist
Phone Advisory Service: 1300 668 908
Palliative Care Queries 24/7
Advance Care Planning Queries 8am-8pm

Guiding principles for medication management in residential aged care facilities, 2012, Commonwealth of Australia, Canberra

Medical care of older persons in residential aged care facilities [silver book], Royal Australian College of General Practitioners

NPS MedicineWise, National Prescribing Service
http://www.nps.org.au/

Medicines Line
Get medicines information: 1300 MEDICINE (1300 633 424), Monday to Friday 9am–5pm AEST

Adverse Medicine Events Line
Report a medicines problem: 1300 134 237, Monday to Friday 9am–5pm AEST

Pain in Residential Aged Care Facilities: Management Strategies, 2005, The Australian Pain Society

Palliative Care Knowledge Network, CareSearch
www.caresearch.com.au

Pharmaceutical Benefits Scheme

Symptom Management at the End of Life, CareSearch

Syringe Driver Drug Compatibilities – Guide to Practice, 2013, Eastern Metropolitan Region Palliative Care Consortium [Victoria], Clinical Group

About the Residential Aged Care Palliative Approach Toolkit

The Residential Aged Care Palliative Approach (PA) Toolkit is a set of resources designed to assist residential aged care providers to implement a comprehensive, evidence-based palliative approach to care for appropriate residents. The PA Toolkit is underpinned by a framework of care that uses a resident’s estimated prognosis to trigger three key processes:

- advance care planning
- palliative care case conferencing
- use of an end of life (terminal) care pathway.

The PA Toolkit includes a range of practical guides, self-directed learning packages, educational DVDs and flipcharts, and clinical and management resources. The resources are all available at http://www.caresearch.com.au/PAToolkit

Background

The PA Toolkit was originally developed and pilot-tested in 2009-2010 by a consortium led by The University of Queensland / Blue Care Research and Practice Development Centre.

In 2013, to further support the implementation of a palliative approach into policy and practice in residential aged care, six new resources were developed together with a national education program on how to use the PA Toolkit. The ‘National Rollout of the PA Toolkit for Residential Aged Care Facilities’ project was led by the Brisbane South Palliative Care Collaborative in partnership with The Australian and New Zealand Society of Palliative Medicine, Leading Age Services Australia, The Royal Australian College of General Practitioners and The University of Queensland / Blue Care Research and Practice Development Centre. The project was funded by the Australian Government Department of Social Services under the Encouraging Better Practice in Aged Care (EBPAC) Initiative.

Further information

Email: patoolkit@health.qld.gov.au
Website: http://www.caresearch.com.au/PAToolkit